Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression
Year: 2011
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Mohamed A Kharfan-Dabaja, Claudio Anasetti, Nathalie Luis, Linda Brand, Janelle Perkins, Hugo F. Fernandez, Jose Leonel Ochoa-Bayona, Taiga Nishihori, Lia E Perez, Ernesto Ayala, Javier Pinilla-Ibarz, Lubomir Sokol, Joseph Pidala, Frederick L Locke, Eduardo M. Sotomayor, Teresa Field, Marcie Tomblyn
Institution: Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2546313647